Teprotumumab for Thyroid-Associated Ophthalmopathy

Terry J. Smith; George J. Kahaly; Daniel G. Ezra; James C. Fleming; Roger A. Dailey; Rosa A. Tang; Gerald J. Harris; Alessandro Antonelli; Mario Salvi; Robert A. Goldberg; James W. Gigantelli; Steven M. Couch; Erin M. Shriver; Brent R. Hayek; Eric M. Hink; Richard M. Woodward; Kathleen Gabriel; Guido Magni; Raymond S. Douglas

doi:10.1056/nejmoa1614949

journal article May 04, 2017

Teprotumumab for Thyroid-Associated Ophthalmopathy

Terry J. Smith

George J. Kahaly Daniel G. Ezra James C. Fleming Roger A. Dailey Rosa A. Tang Gerald J. Harris Alessandro Antonelli

Mario Salvi Robert A. Goldberg James W. Gigantelli Steven M. Couch Erin M. Shriver Brent R. Hayek Eric M. Hink Richard M. Woodward Kathleen Gabriel Guido Magni Raymond S. Douglas

New England Journal of Medicine Vol. 376 No. 18 pp. 1748-1761 · Massachusetts Medical Society

View at Publisher Save 10.1056/nejmoa1614949

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

10.1056/nejmra1510030

[2]

10.1016/0360-3016(89)90073-4

[3]

10.1210/jc.2012-2389

[4]

10.1210/jc.2010-1962

[5]

10.1530/eje-14-0712

[6]

10.1210/jc.2012-2758

[7]

10.1210/jc.86.8.3562

[8]

10.1055/s-0035-1559633

[9]

10.1007/s40618-016-0478-9

[10]

10.1016/0140-6736(93)91475-2

[11]

10.1210/jc.83.3.998

[12]

10.1210/jc.2009-1614

[13]

Tabasum A Endocrinol Diabetes Metab Case Rep (2016)

[14]

10.4049/jimmunol.170.12.6348

[15]

10.1210/endo-119-2-940

[16]

10.1210/en.2011-0231

[17]

10.1124/pr.109.002469

[18]

10.4049/jimmunol.181.6.4397

[19]

10.4049/jimmunol.178.5.3281

[20]

10.4049/jimmunol.181.8.5768

[21]

10.1210/jc.2014-1580

[22]

10.1158/1078-0432.ccr-09-3220

[23]

10.1530/eje.1.02230

[24]

10.1136/bjo.82.7.773

[25]

Rootman DB Ophthal Plast Reconstr Surg

[26]

Wu CY Ophthal Plast Reconstr Surg

[27]

10.1046/j.1365-2265.2001.01241.x

[28]

10.1016/j.ophtha.2006.10.036

[29]

10.3109/08916939309014643

[30]

10.1210/jc.2004-0716

[31]

10.1210/jc.2012-2270

[32]

10.1210/jc.2013-1004

[33]

10.1210/jc.2012-1771

[34]

10.1210/jc.2016-1315

[35]

10.1200/jco.2010.34.0000

[36]

10.1200/jco.2011.36.6799

[37]

10.1111/bcp.12228

[38]

10.1210/jc.2014-2572

[39]

10.1210/jc.2014-3014

[40]

10.4049/jimmunol.173.5.3564

Cited By

631

Global Trends in Eyelid Disease associated with Thyroid Ophthalmopathy (1975-2025): A Systematic Review and Meta-Analysis

Niraj Kumar Yadav, PRIYANKA SHARMA · 2026

Journal of Ophthalmology and Advanc...

A statement from Japanese experts on the appropriate use of teprotumumab for active thyroid eye disease

Toyoyoshi Uchida, Ichiro Yamauchi · 2026

Thyroid Science

Temporal Glycemic Patterns During IGF-1R Inhibitor Therapy for Thyroid Eye Disease: A Pooled Analysis of Two Clinical Trials

Wei Zhao, Tianyuan Li · 2026

Thyroid

Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study

Natan Lishinsky-Fischer, Rena Pollack · 2026

Thyroid

The Management of Thyroid Eye Disease: From Current Practice to Future Perspectives

Navnit Kaur Dhaliwal, Lubna Razzaq · 2025

Cureus

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy

Xuejiao Cui, Futao Wang · 2023

Frontiers in Immunology

Teprotumumab for the treatment of thyroid eye disease

Poupak Fallahi, Francesca Ragusa · 2023

Expert Opinion on Biological Therap...

Management of eyelid retraction related to thyroid eye disease

Tammy H. Osaki, Lucas G. Monteiro · 2022

Taiwan Journal of Ophthalmology

Recent advances in thyroid eye disease: An overview

Sahil Agrawal, Rajendra Prakash Maurya · 2021

IP International Journal of Ocular...

The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves’ ophthalmopathy

Hadi Khazaei, Danesh Khazaei · 2021

Experimental Eye Research

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab

Shoaib Ugradar, Jenna Braun · 2021

Plastic and Reconstructive Surgery...

Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy

Ji Sun Paik, Sung-Eun Kim · 2020

Immunobiology

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

Luigi Bartalena, Eliana Piantanida · 2020

Frontiers in Endocrinology

Th1 Chemokines in Autoimmune Endocrine Disorders

Poupak Fallahi, Silvia Martina Ferrari · 2019

The Journal of Clinical Endocrinolo...

Therapeutic Targeting of the IGF Axis

Eliot Osher, Valentine M. Macaulay · 2019

Cells

A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy

Patrick Marcinkowski, Inna Hoyer · 2019

Thyroid

Approach to Diplopia

Christopher C. Glisson · 2019

Continuum

New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor

Terry J Smith · 2018

F1000Research

Thyroid eye disease

Zhen Li, Dean M. Cestari · 2018

Current Opinion in Ophthalmology

Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial

Rathie Rajendram, Peter N Taylor · 2018

The Lancet Diabetes & Endocrino...

Metrics

631

Citations

40

References

Details

Published: May 04, 2017
Vol/Issue: 376(18)
Pages: 1748-1761

Authors

T

Terry J. Smith

University of Rochester Cancer Center and Departments of Microbiology and Immunology, Pediatrics, and Environmental Medicine, University of Rochester, Rochester 14642; Division of Molecular and Cellular Medicine, Department of Medicine, and Department of Biochemistry and Molecular Biology, Albany Medical College, and Samuel S. Stratton Veterans Affairs Medical Center, Albany, New York 12208

G

George J. Kahaly

From Cedars–Sinai Medical Center, Los Angeles (R.S.D., A.P.); Johannes Gutenberg University Medical Center, Mainz (G.J.K.), and University Hospital Essen, Essen (A.E.) — both in Germany; Horizon Therapeutics, Lake Forest, IL (S.S., E.H.Z.T., R.P., J.W.S., T.V., R.J.H.); University of Tennessee Health Science Center, Memphis (J.C.F., B.T.F.); University of Pisa, Pisa (C.M., M.M., A.A.), and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.S.) — both in Italy; Oregon Health and...

From Cedars–Sinai Medical Center, Los Angeles (R.S.D., A.P.); Johannes Gutenberg University Medical Center, Mainz (G.J.K.), and University Hospital Essen, Essen (A.E.) — both in Germany; Horizon Therapeutics, Lake Forest, IL (S.S., E.H.Z.T., R.P., J.W.S., T.V., R.J.H.); University of Tennessee Health Science Center, Memphis (J.C.F., B.T.F.); University of Pisa, Pisa (C.M., M.M., A.A.), and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.S.) — both in Italy; Oregon Health and...

From Cedars–Sinai Medical Center, Los Angeles (R.S.D., A.P.); Johannes Gutenberg University Medical Center, Mainz (G.J.K.), and University Hospital Essen, Essen (A.E.) — both in Germany; Horizon Therapeutics, Lake Forest, IL (S.S., E.H.Z.T., R.P., J.W.S., T.V., R.J.H.); University of Tennessee Health Science Center, Memphis (J.C.F., B.T.F.); University of Pisa, Pisa (C.M., M.M., A.A.), and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.S.) — both in Italy; Oregon Health and...

A

Alessandro Antonelli

From Cedars–Sinai Medical Center, Los Angeles (R.S.D., A.P.); Johannes Gutenberg University Medical Center, Mainz (G.J.K.), and University Hospital Essen, Essen (A.E.) — both in Germany; Horizon Therapeutics, Lake Forest, IL (S.S., E.H.Z.T., R.P., J.W.S., T.V., R.J.H.); University of Tennessee Health Science Center, Memphis (J.C.F., B.T.F.); University of Pisa, Pisa (C.M., M.M., A.A.), and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.S.) — both in Italy; Oregon Health and...

M

Mario Salvi

From Cedars–Sinai Medical Center, Los Angeles (R.S.D., A.P.); Johannes Gutenberg University Medical Center, Mainz (G.J.K.), and University Hospital Essen, Essen (A.E.) — both in Germany; Horizon Therapeutics, Lake Forest, IL (S.S., E.H.Z.T., R.P., J.W.S., T.V., R.J.H.); University of Tennessee Health Science Center, Memphis (J.C.F., B.T.F.); University of Pisa, Pisa (C.M., M.M., A.A.), and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.S.) — both in Italy; Oregon Health and...

From the Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Kellogg Eye Center, Ann Arbor, Michigan; the 2Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Med

Cite This Article

Terry J. Smith, George J. Kahaly, Daniel G. Ezra, et al. (2017). Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine, 376(18), 1748-1761. https://doi.org/10.1056/nejmoa1614949

Teprotumumab for Thyroid-Associated Ophthalmopathy

You May Also Like